CAGEKID
Cancer Genomics of the Kidney
| Coordinatore | FONDATION JEAN DAUSSET CENTRE D'ETUDE DU POLYMORPHISME HUMAIN FONDATION
Organization address
address: RUE JULIETTE DODU 27 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 13˙747˙768 € |
| EC contributo | 10˙500˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-two-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-03-01 - 2014-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FONDATION JEAN DAUSSET CENTRE D'ETUDE DU POLYMORPHISME HUMAIN FONDATION
Organization address
address: RUE JULIETTE DODU 27 contact info |
FR (PARIS 10) | coordinator | 3˙007˙900.00 |
| 2 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 1˙852˙326.00 |
| 3 |
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER
Organization address
address: Cours Albert-Thomas 150 contact info |
FR (LYON CEDEX 08) | participant | 1˙126˙500.00 |
| 4 |
Centre Bioengineering of the Russian academy of sciences
Organization address
address: Prosp. 60-let Oktiabria 7-1 contact info |
RU (Moscow) | participant | 815˙151.44 |
| 5 |
RUSSIAN RESEARCH CENTRE KURCHATOV INSTITUTE
Organization address
address: Kurchatov square 1 contact info |
RU (MOSCOW) | participant | 804˙092.90 |
| 6 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 691˙930.75 |
| 7 |
PROTIVORAKOVOE OBSHESTVO ROSSII
Organization address
address: KASHIRSKOYE SHOSSE 24 contact info |
RU (MOSKVA) | participant | 530˙500.00 |
| 8 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 514˙099.00 |
| 9 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 485˙375.00 |
| 10 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 285˙600.00 |
| 11 |
UNIVERZITA KARLOVA V PRAZE
Organization address
address: Ovocny trh 5 contact info |
CZ (PRAHA 1) | participant | 175˙500.00 |
| 12 |
LATVIJAS UNIVERSITATES MATEMATIKAS UN INFORMATIKAS INSTITUTS
Organization address
address: RAINA BULVARIS 29 contact info |
LV (RIGA) | participant | 149˙774.00 |
| 13 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 34˙244.00 |
| 14 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 27˙007.00 |
| 15 |
ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING MCGILL UNIVERSITY
Organization address
address: SHERBROOKE STREET WEST 845 contact info |
CA (MONTREAL) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The International Cancer Genome Consortium (ICGC) has the goal of obtaining a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumour types and/or subtypes, with the aim of elucidating the genomic changes present in the many forms of cancers that contribute to the burden of disease throughout the world. We present a proposal for a European contribution to this effort through application of state-of-the-art approaches to the genomics of the most common form of renal cell cancer (RCC). RCC is of particular importance within Europe where the highest global incidence rates are observed. Disease incidence has increased over the last two decades, and it is now the 8th most common cancer in the EU. CAGEKID brings clinical and epidemiological resources that are unique worldwide together with the necessary genetics and genomics expertise required for this effort. In the first phase of the study, we will provide a full genomic characterisation of 100 matched pairs of DNA extracted from the tumour and constitutional samples. DNA will be completely sequenced, and the data brought together with those from whole genome transcript and methylation analyses. Follow-up studies of potential targets will be made in further samples. The results acquired will be relied to targeted protein analyses. The primary data will be made available to the scientific community, and the programme will contribute to establishing norms for the manipulation and storage of biological samples. CAGEKID will provide the first systematic analysis of this tumour site providing new insights into disease aetiology with application for diagnosis and treatment. It addresses a major need to identify new biological markers for renal cell cancer, one of very few tumour types for which there are currently no biological markers in routine clinical use. Renal cancer is not yet supported by any of the members of the ICGC.'